drugset / Trial / NCT04096690
Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This open-label, single arm study will evaluate the efficacy and safety of anti-PD-1 antibody in combination with pegaspargase in treatment of newly diagnosed advanced stage NK/T-cell lymphoma.
Timeline
- Start
- 2019-09-10
- Primary completion
- 2021-12
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegaspargase | Protein / enzyme biologic | 3750 iu | Intramuscular |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |